Toggle navigation
About Us
Overview
Management Team
Press Room
Careers
Contact us
Healthcare Professionals
Overview
Licenses and Certifications
Publications
Billing Information
Investors
Patients
Overview
Breast Cancer
Metastatic Cancer
Glossary
Billing Information
Make a Payment
Products
Order
Physician Portal
Order a Test
Press Room
1
2
3
4
5
6
7
Biotheranostics Announces Inclusion of Breast Cancer Index
™
in the National Comprehensive Cancer Network (NCCN)
Biotheranostics appoints Mark D. Pegram, MD as Chief Medical Consultant for Breast Oncology
Breast Cancer Index
™
demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients
Biotheranostics to premiere new data on Breast Cancer Index
™
and prediction of endocrine therapy benefit at SABCS 2020
Biotheranostics' Breast Cancer Index
™
IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors
Biotheranostics CancerTYPE ID
®
aids in patient selection for immunotherapy
Biotheranostics to Present at the LifeSci Partners Summer Symposium
Biotheranostics presents new studies of the Breast Cancer Index
®
at the 2020 ASCO conference
Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial
Biotheranostics Announces Chief Commercial Officer
Biotheranostics’ Pivotal Clinical Study of the Breast Cancer Index® featured on the cover of the Annals of Oncology
Biotheranostics Launches Not Another Minute Campaign for its Breast Cancer Index
®
Test
Biotheranostics to Present New Data Expanding the Clinical Utility of Breast Cancer Index® at the 42nd Annual San Antonio Breast Cancer Symposium
1
2
3
4
5
6
7